Insmed Competitors
| INSM Stock | USD 148.55 0.99 0.66% |
Insmed vs Takeda Pharmaceutical Correlation
Pay attention - limited upside
The correlation between Insmed Inc and TAK is -0.9 (i.e., Pay attention - limited upside) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Insmed Inc and TAK in the same portfolio, assuming nothing else is changed.
Moving together with Insmed Stock
Moving against Insmed Stock
| 0.77 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.68 | ENGN | enGene Holdings Common | PairCorr |
| 0.55 | DSGN | Design Therapeutics | PairCorr |
| 0.44 | 63E | ONWARD MEDICAL BV | PairCorr |
| 0.37 | KYTX | Kyverna Therapeutics | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Insmed's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Insmed Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Insmed and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Insmed and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Insmed Inc does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Insmed Stock performing well and Insmed Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Insmed's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ONC | 1.91 | 0.10 | 0.04 | 0.22 | 1.82 | 4.39 | 14.16 | |||
| A | 1.22 | (0.29) | 0.00 | (0.16) | 0.00 | 2.90 | 7.85 | |||
| RMD | 1.12 | 0.05 | 0.02 | 0.15 | 1.44 | 2.13 | 5.71 | |||
| IQV | 1.53 | (0.31) | 0.00 | (0.13) | 0.00 | 3.30 | 15.97 | |||
| ALC | 1.14 | 0.04 | 0.03 | 0.13 | 1.01 | 3.24 | 7.05 | |||
| HLN | 1.01 | 0.24 | 0.14 | 1.03 | 0.98 | 2.81 | 6.06 | |||
| CAH | 1.05 | 0.21 | 0.07 | (0.49) | 1.21 | 2.54 | 10.21 | |||
| GEHC | 1.49 | (0.02) | 0.00 | 0.07 | 1.74 | 3.38 | 7.77 | |||
| HUM | 2.13 | (0.65) | 0.00 | (0.31) | 0.00 | 3.79 | 27.31 | |||
| TAK | 0.89 | 0.41 | 0.46 | 1.64 | 0.00 | 2.49 | 4.49 |
Cross Equities Net Income Analysis
Compare Insmed Inc and related stocks such as BeiGene, Agilent Technologies, and ResMed Inc Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ONC | (7.5 M) | (7.5 M) | (7.5 M) | (7.5 M) | (18.3 M) | (57.1 M) | (119.2 M) | (93.1 M) | (673.8 M) | (948.6 M) | (1.6 B) | (1.5 B) | (2 B) | (881.7 M) | (644.8 M) | (580.3 M) | (609.3 M) |
| A | 257 M | 1.2 B | 724 M | 549 M | 401 M | 460 M | 684 M | 316 M | 1.1 B | 719 M | 1.2 B | 1.3 B | 1.2 B | 1.3 B | 1.3 B | 1.5 B | 1.6 B |
| RMD | 800 K | 254.8 M | 307.1 M | 345.3 M | 352.9 M | 352.4 M | 342.3 M | 315.6 M | 404.6 M | 621.7 M | 474.5 M | 779.4 M | 897.6 M | 1 B | 1.4 B | 1.6 B | 1.7 B |
| IQV | 160.6 M | 241.8 M | 177.5 M | 226.6 M | 356.4 M | 387.2 M | 115 M | 1.3 B | 259 M | 191 M | 279 M | 966 M | 1.1 B | 1.4 B | 1.4 B | 1.4 B | 1.4 B |
| ALC | 931 M | 296.3 M | 296.3 M | 296.3 M | 296.3 M | 296.3 M | (170 M) | 256 M | (227 M) | (656 M) | (531 M) | 376 M | 335 M | 974 M | 1 B | 916.2 M | 962 M |
| HLN | 655 M | 655 M | 655 M | 655 M | 655 M | 655 M | 655 M | 655 M | 655 M | 655 M | 1.1 B | 1.4 B | 1.1 B | 1 B | 1.4 B | 1.7 B | 1.2 B |
| CAH | 6 M | 1.1 B | 334 M | 1.2 B | 1.2 B | 1.4 B | 1.3 B | 256 M | 1.4 B | (3.7 B) | 611 M | (938 M) | 330 M | 852 M | 1.6 B | 1.8 B | 1.9 B |
| GEHC | 1.5 B | 1.5 B | 1.5 B | 1.5 B | 1.5 B | 1.5 B | 1.5 B | 1.5 B | 1.5 B | 1.5 B | 13.8 B | 2.2 B | 1.9 B | 3.1 B | 2 B | 2.1 B | 3.1 B |
| TAK | 119.6 B | 124.2 B | 131.2 B | 106.7 B | (145.8 B) | 80.2 B | 114.9 B | 186.9 B | 109.1 B | 44.2 B | 376 B | 230.1 B | 317 B | 144.1 B | 107.9 B | 97.1 B | 155.3 B |
Insmed Inc and related stocks such as BeiGene, Agilent Technologies, and ResMed Inc Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Insmed Inc financial statement analysis. It represents the amount of money remaining after all of Insmed Inc operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Insmed Competitive Analysis
The better you understand Insmed competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Insmed's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Insmed's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Insmed Competition Performance Charts
Five steps to successful analysis of Insmed Competition
Insmed's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Insmed Inc in relation to its competition. Insmed's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Insmed in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Insmed's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Insmed Inc, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Insmed position
In addition to having Insmed in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Climate Change Thematic Idea Now
Climate Change
Large and medium sized entities that are committing to fully or partially replace some traditional services or products with renewables sources of energy in order to combat global climate change. The Climate Change theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Climate Change Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Insmed Correlation with its peers. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Will Biotechnology sector continue expanding? Could Insmed diversify its offerings? Factors like these will boost the valuation of Insmed. Market participants price Insmed higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Insmed data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (6.15) | Revenue Per Share | Quarterly Revenue Growth 0.524 | Return On Assets | Return On Equity |
Investors evaluate Insmed Inc using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Insmed's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Insmed's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Insmed's market price signifies the transaction level at which participants voluntarily complete trades.